Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

Breaking Bad B cell-orchestrated tolerization of T cell-dependent B cell-mediated autoimmune diseases

Coordinator
Klinikum Der Technischen Universität München (tum Klinikum), Germany
Runs
1 February 2026 to 31 January 2031
Status
Running
EU funding
€2.4m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101198426

What the project is doing

In the project's own words, from its summary on CORDIS.

Failure of thymic tolerance may result in severe autoimmune diseases that target the central nervous system (CNS), including Multiple Sclerosis (MS), Myelin Oligodendrocyte Glycoprotein (MOG)-associated Disease (MOGAD), and Neuromyelitis Optica Spectrum Disorders (NMOSD). Recently, we discovered a new layer of thymic tolerance in that thymic B cells get licensed to present activation-induced autoantigens, among them AQP4 (the target antigen in NMOSD).

Thymic B cells are necessary and sufficient to purge the T cell repertoire of AQP4-specific clones. In BREAKING BAD, we will investigate in depth how thymic B cells shape the AQP4-specific T cell repertoire by either deleting AQP4-specific conventional T cells or agonist-selecting Foxp3+ Treg cells. To understand B cell-intrinsic and extrinsic checkpoints of this process, we will use genetic means to disrupt thymic tolerance to AQP4.

Since we have cloned a variety of AQP4-specific TCRs, we are now in the position to track fate decisions and functional phenotypes of naïve T cells that react against AQP4, which is – in contrast to MOG – not only expressed in the CNS but also in peripheral organs. Finally, our data indicate that amyloid precursor protein (APP), associated with cerebral amyloid angiopathy and Alzheimer's disease, is an autoantigen that is – very similar to AQP4 – induced in B cells upon CD40 stimulation and expressed in thymic B cells.

Therefore, we will investigate the APP-specific T cell repertoire and its ability to provide T cell help for the generation of anti-amyloid Abeta antibodies upon disruption of B cell-mediated tolerance to Abeta peptides by conditional genetic ablation of APP in B cells. In summary, BREAKING BAD will explore the significance of B cell-mediated tolerance for CNS autoantigens. We anticipate that our experiments will revolutionize the understanding and perhaps potential treatment options of CNS autoimmunity but also of major degenerative disorders like Alzheimer's disease.

Topics

Who is involved

OrganisationCityCountryRole
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI